linjc16/ctgov huggingface dataset:
Heart Rate Changes Following the Administration of Sugammadex

Study Overview
=================
Brief Summary
-----------------
This a prospective study when the clinician decides to use sugammadex, heart rate will be recorded every minute for 15 minutes following its administration. If bradycardia occurs and a clinical decision is made to treat it, the medications and doses used will be recorded.

Official Title
-----------------
Heart Rate Changes Following the Administration of Sugammadex

Conditions
-----------------
Bradycardia

Intervention / Treatment
-----------------
* Other: Recording heart rate changes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient age 0-18 years Anesthetic plan includes NMB reversal with sugammadex Exclusion Criteria: Sugammadex not used during the case

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bradycardia during sugammadex administration<br>Recording any heart rate changes during planned administration of sugammadex. | Other: Recording heart rate changes<br>* Recording heart rate changes during planned sugammadex administration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bradycardia during sugammadex administration |  | intraoperative |
Cancer Patient Perspectives During COVID-19

Study Overview
=================
Brief Summary
-----------------
A web-based survey will be emailed to all adult women diagnosed with invasive breast cancer or ductal carcinoma in situ who have been seen as surgical consultations within the last year (06/01/19-06/01/20).

Detailed Description
-----------------
A web-based survey will be emailed to all adult women diagnosed with invasive breast cancer or ductal carcinoma in situ who have been seen as surgical consultations within the last year (06/01/19-06/01/20). This will ensure that patients at various stages of treatment are included, from initial diagnosis into survivorship. This will allow the investigators to assess changes to initial consultations, surgeries, chemotherapy, and radiation, as well as patient perspectives as it relates to these changes. The web-based surveys will be given via Redcap. The study team will use a validated questionnaire developed at the University of Miami (Penedo, 2020), which includes a combination of multiple-choice questions, Likert scale ratings, and yes/no questions. A list of potential questions is listed below. A group of patients will be contacted for semi-structured interviews via telephone as well if (1) patients indicate willingness to participate on a separate RedCap survey or (2) if the patient does not respond to this survey. Phone interviews will be recorded and transcribed verbatim. Multiple members of the research team will separately code the information and evaluate for themes.

Official Title
-----------------
Patient Perspectives in Breast Cancer Care During COVID-19

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult females with diagnosis of invasive breast cancer or ductal carcinoma in situ, seen as surgical consultation between 06/01/19-06/01/20 Exclusion Criteria: Males Patients with non-cancer diagnoses Patients with no history of breast cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with changes implemented to breast cancer treatment | Number of participants with changes implemented to breast cancer treatment during the COVID-19 pandemic | 12 months | 
| Number of participants with treatment concerns during COVID-19 pandemic | Patients with treatment concerns during the COVID-19 pandemic | 12 months | 
| Number of participants with effects of COVID-19 on psychological, social, and physical well-being of breast cancer patients | Number of participants with effects of COVID-19 on psychological, social, and physical well-being of breast cancer patients | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19
Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP

Study Overview
=================
Brief Summary
-----------------
To assess the effectiveness of a protocol of ovarian hyperstimulation combining urinary gonadotrophins + recombinant gonadotrophins, to achieve clinical pregnancy in females undergoing IVF. Study hypothesis: to assess the effectiveness of protocols combining urinary gonadotrophins + recombinant gonadotrophins

Official Title
-----------------
Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP Within a Protocol of Controlled Ovarian Hyperstimulation in IVF in Normoresponders Women Undergoing Downregulation With GnRH Antagonist

Conditions
-----------------
Sterility

Intervention / Treatment
-----------------
* Drug: hMG-HP/r-FSH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 18-38 years Body mass index (BMI) between 18 and 30 Women classified as normogonadotrophin patients. Not more than 3 previous cycles of ART (assisted reproductive technology) Testosterona, FSH (follicle-stimulating hormone), LH (luteinizing hormone) and Prolactin serum levels during the early folicular phase (days 2-4 of the cycle) within the laboratory normal range No administration of clomiphen citrate or gonadotropins during the month prior to the start of the study Exclusion Criteria: Failure in previous cycles of assisted reproduction IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) Seminal samples not apt for IVF-ICSI (according to the criteria of each center). Evidence of significant bacterial infection in the seminogram of the couple in the preceding 6 months Data suggestive of possible ovarian failure Antecedents of severe ovarian hyperstimulation syndrome (OHSS) Important systemic disease Pregnancy or contraindication to pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hMG-HP/r-FSH<br>Patients with a condition | Drug: hMG-HP/r-FSH<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical pregnancy rate |  | 16 days |
Naltrexone for Relapse Prevention

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the safety and effectiveness of an injectable slow releasing preparation of naltrexone to reduce alcohol consumption and risk of relapse in alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo injection for a total of three months, with two subsequent followup visits spanning a 6- month period.

Official Title
-----------------
Etiology and Treatment of Alcohol Dependence

Conditions
-----------------
Alcoholism

Intervention / Treatment
-----------------
* Drug: naltrexone (Revia)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meets criteria for alcohol dependence. Abstinent from alcohol for a period of at least 3 days prior to beginning of study. Able to read English and complete study evaluations. Females who are postmenopausal, have had surgical sterilization, or use reliable means of birth control. Exclusion Criteria: Meets criteria for dependence on a psychoactive substance other than alcohol and nicotine and/or cannabis. Prior history of opioid dependence. Regular use of psychoactive drugs including anxiolytics and antidepressants. Prior treatment with naltrexone. Current use of disulfiram. Psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current mania). Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid, or cardiac disease. Abstinent longer than 28 days prior to randomization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: naltrexone (Revia)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Assessment of S-ICD Eligibility With 12-Lead ECG

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to develop an approach to determine eligibility for subcutaneous ICD by analyzing routine clinical 12-lead electrocardiogram.

Official Title
-----------------
Assessment of Subcutaneous Implantable Cardioverter Defibrillator Eligibility With 12-lead Electrocardiogram

Conditions
-----------------
Implantable Defibrillator User

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical condition, predisposing patient to life-threatening ventricular arrhythmias, eligible for currently approved ICD indications for primary or secondary prevention of sudden cardiac death Exclusion Criteria: Acute medical condition (e.g. acute myocardial infarction, severe trauma, post-surgery, admitted to ICU) End stage organ failure Pregnancy Patient, legal guardian or authorized representative is unable or unwilling to cooperate or give written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amplitudes of R- and T-waves (and R/T ratios) on a special precordial ECG | Amplitudes of R- and T-waves (and R/T ratios) on a special ECG (recorded for Subcutaneous ICD eligibility assessment) | at the day of ECG recording (cross-sectional study) |
Reverse-Loop Upper Arm Arteriovenous Graft

Study Overview
=================
Brief Summary
-----------------
Background: A conventional configured prosthetic arteriovenous graft (AVG) usually wastes most upper arm vessels that a reverse-loop design may conserve. This study examined the feasibility of the AVG construction and its outcome. Methods: Retrospective review of clinical outcomes of reverse-loop upper arm AVG patients. Measures included hemodialysis function, duplex scan, procedural complications, and follow-up interventions

Official Title
-----------------
Reverse-Loop Upper Arm Arteriovenous Graft for Chronic Hemodialysis

Conditions
-----------------
Blood Vessel Prosthesis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: compromized forearm and elbow options Exclusion Criteria: unstable

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>surgical outcome, observation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional event-free primary patency |  | event-free time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measures included hemodialysis function, duplex scan, procedural complications, and follow-up interventions. |  | events (month) |
Essential Oils on Anxiety of Patients Suffering From Cancer

Study Overview
=================
Brief Summary
-----------------
This study evaluates the impact of essential oils massage on anxiety of patients who are suffering from cancer at a metastasis stage. Half of patients will be massaged first by essential oils and then by oil only. The other half will be massaged first by oil and then by essential oils.

Official Title
-----------------
Impact of Essential Oils on Anxiety of Patients Suffering From Metastasis Cancer - Feasibility Study

Conditions
-----------------
Neoplasm Metastasis

Intervention / Treatment
-----------------
* Other: Essential oils massages
* Other: Oil massages


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult suffering from cancer at a metastatic stage Life expectancy > 15 days, assessed by investigator Hospitalized at the Chevrel unit from Centre Eugène Marquis, palliative unit care, for more than 15 days Regular anxiolytic treatment or imperative need to introduce anxiolytic treatment (assessed by investigator) within 48 hours following his hospitalization entry > 18 years Exclusion Criteria: Patient already recruited in a therapeutic trial Patient not covered by a social security system Pregnant or likely pregnant patient, breastfeeding patient Allergy to any component of essential oils mixture and vegetable oils : bitter orange petitgrain, fine lavender, ylang-ylang, macadamia Minors, people deprived of their liberty or protected people, Impaired cognitive functions making impossible to obtain informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Essential oils then oil massages<br>Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days | Other: Essential oils massages<br> <br> Other: Oil massages<br> <br> |
| Experimental: Oil then essential oils massages<br>Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days | Other: Essential oils massages<br> <br> Other: Oil massages<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anxiolytic consumption | Anxiolytic consumption will be assessed at day 7 at the end of each phase | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anxiety
Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Four Hospital of the Alpine Region

Study Overview
=================
Brief Summary
-----------------
The PACAAP study aims to report the seroprevalence of SARS-CoV-2 IgG antibodies among HCWs testing during the massive campaign screening set up in France by French ministry of Health and national authorities in four hospital of the Alpine region.

Detailed Description
-----------------
In France during the first wave of the pandemic, 30,230 symptomatic healthcare workers had been reported positive. Yet, the prevalence of the infection in French healthcare workers remains unknown as it mostly reflect symptomatic infections. Also, the prevalence of infection was reported being higher in male healthcare workers, and in those having patients' facing roles. However, the impact of the level of exposure to SARS-CoV-2, the use of personal protective equipment and hospital organization to prevent infection and spread remains unclear. Our study aims to report the seroprevalence of SARS-CoV-2 infection among French healthcare workers after the first wave of the pandemic. It also aims to explore the impact of the type of occupations and the level of exposure to the viruses on the seroprevalence of infection.

Official Title
-----------------
Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Five Hospital of the Alpine Region

Conditions
-----------------
Covid19, Health Care Worker

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospital staff employee Employed in one of the participating centers Volunteers to perform SARS-CoV-2 serology Permanent or occasional staff (temporary workers, short contracts) Caregivers or not (medical, paramedical, administrative, technical staff) Exclusion Criteria: Staff who are not working at a participating center while participating in the study Person under guardianship or curatorship Opposition to data collection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-CoV-2 prevalency among hospital health care professionals | Number of Health Care Worker with an antibody test (IgG) positive for SARS-CoV2 | Day 1 |
Early Non Invasive Ventilation in Immuno-compromized Patients With Acute Respiratory Failure.

Study Overview
=================
Brief Summary
-----------------
Assess the superiority of early non invasive ventilation in comparison to Oxygen therapy only, for immuno-compromized patients with acute respiratory failure

Official Title
-----------------
Early Non Invasive Ventilation in Immuno-compromized Patients With Acute Respiratory Failure. A Prospective Randomized Clinical Trial.

Conditions
-----------------
Adult, Acute Respiratory Failure Admitted in ICU, Immuno Compromized

Intervention / Treatment
-----------------
* Procedure: Early non invasive ventilation
* Procedure: Oxygen therapy only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years old ICU admission Acute respiratory failure defined by (PaO2<60 mmHg at room air) or (polypnea >30/min or dyspnea at rest) or respiratory distress. Since less than 72 hours. Immuno compromized patient defined by solid tumor (treated since less than 5 years) or haematological malignancy (treated since less than 5 years) or Solid organ transplantation or Stem cell transplantation or Immunosuppressive treatment (steroid > 1mg/kg/d or >1 month or other immunosuppressive treatment >1 month) Exclusion Criteria: Hypercapnia >50 mmHg or increased of hypercapnia >10 mmHg under Oxygen treatment Need of immediate mechanical ventilation Obvious cardiogenic oedema Vasopressor use >0.03 µg/kg/min Glasgow Score <13 End of life decision Acute myocardial infarction Patient refusal Pregnancy No national health insurance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Early non invasive ventilation<br>Early non invasive ventilation | Procedure: Early non invasive ventilation<br> <br> |
| Active Comparator: Oxygen therapy only<br>Oxygen therapy only | Procedure: Oxygen therapy only<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Day 28 Mortality |  | Day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Needs of mechanical ventilation |  | Day 28 | 
| SOFA Score |  | Hour 72 | 
| Nosocomial infection |  | day 28 | 
| Length of stay in ICU |  | Day 28 | 
| performance status (OMS scale ranging from 0-perfect status- to 4-moribund) |  | 6 Months |
IMPACTS OF BRAXTON-HICKS CONTRACTIONS ON COMPUTERISED CARDIOTOCOGRAPHY PARAMETERS: A POTENTIAL LINK.

Study Overview
=================
Brief Summary
-----------------
Several types of research examined the relationship of Braxton-Hicks contractions and uterine flow. Nevertheless, no one considered the relationship of the maternal perception of Braxton-Hicks contractions with the fetal wellbeing quantifies through computerised cardiotocography. Our study wants to estimate the correlation between the maternal perception of Braxton-Hicks contractions and antepartum computerised cardiotocography parameters.

Official Title
-----------------
IMPACTS OF BRAXTON-HICKS CONTRACTIONS ON COMPUTERISED CARDIOTOCOGRAPHY PARAMETERS: A POTENTIAL LINK.

Conditions
-----------------
Braxton Hicks' Contractions

Intervention / Treatment
-----------------
* Diagnostic Test: antepartum computerised cardiotocography analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nonlaboring women with a term uncomplicated singleton pregnancy Exclusion Criteria: complicated singleton pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 48 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| nonlaboring term singleton pregnancies<br>All patients had an uncomplicated pregnancy and to define a pregnancy uncomplicated we adopted Chappell's definition: a normotensive pregnancy, delivered at >37 weeks, ending in a live-born baby who was not small for gestational age and did not have any other notable pregnancy complications | Diagnostic Test: antepartum computerised cardiotocography analysis<br>* A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the comparison of the antepartum computerised cardiotocography between the patients with Braxton-Hicks contractions and the patients without uterine activity | External cCTG was completed at least 20 minutes (maximum 60 minutes), two transducers were placed on the maternal abdomen: one over the fetal heart level and the other one at the uterine fundus. For each cCTG, the following data were evaluated: Basal FHR | pre-intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Braxton Hicks' contractions, uterine contractions, fetal well-being, Computerized cardiotocography (cCTG), Fetal heart rate (FHR), Pregnancy